Plan B for Part B?

PhRMA and BIO's "hell no" responses to CMS's plan to change the way Medicare Part B pays for drugs have set the stage for a confrontation that will test the industry's ability to fend off future threats to its pricing practices.

The CMS proposal, which is structured as an experiment, includes a plan to wean physicians and outpatient facilities from reimbursement based on the cost of administered drugs. This phase is slated to be implemented this year...